摘要
目的 观察双路化疗 [经导管肝动脉化疗栓塞 (TACE)联合 B超引导下经皮经肝细针穿刺门静脉化疗 (PVE) ]治疗原发性肝细胞肝癌 (HCC)的疗效。方法 HCC患者 6 8例进行 TACE+PVE,同期选择单纯行TACE患者 2 4例作为对照。结果 TACE+PVE组和单纯 TACE组的总有效率 (完全缓解 +部分缓解 +无变化 )分别是 5 7.4%和 37.5 %,两组有显著性差异 (P<0 .0 1) ,门静脉癌栓消失 +缩小率两组分别是 5 5 .9%和 2 5 %(P<0 .0 5 )。 1、2、3年生存率 TACE组分别是 6 2 .5 %、37.5 %、2 0 .8%;TACE+PVE组分别是 91.2 %、6 1.8%、39.7%(P<0 .0 5 )。结论 TACE+PVE治疗 HCC优于单纯 TACE;B超引导下细针穿刺门静脉行 PVE操作简便 ,并发症少 ,有临床推广价值。
Objective To study the effect of combined chemotherapy by transcatheter arterial (TACE)and Ultrasound-Guided portal vein embolization (PVE)treating hepatocellular carcinoma.Methods Chemotherapy embolization 68 patients with primary hepatocellular carcinoma(HCC) were treated by TACE+PVE, 24 patients with primary HCC were treated only by TACE was contral group.Results The total response rate was 57.4% in TACE+PVE group and 37.5% in TACE group (P<0.001). The tumor thrombi of 55.9% in TACE+PVE group and 25% in TACE group became lessened or resolved (P<0.05). The 1? 2? 3 years survival rate was 62.5%, 37.5% and 20.8% in TACE group and 91.2%? 61.8% and 39.7% in TACE+PVE group repectively(P<0.05).Conclusion The method of TACE +PVE is more effective than that of TACE alone in treatment of patient with primary HCC.The method of PVE is easy, safe and should be widely used in clinical practice.
出处
《山东医药》
CAS
北大核心
2003年第27期16-18,共3页
Shandong Medical Journal
关键词
原发性肝癌
肝动脉化疗栓塞
门静脉化疗
治疗
疗效
Hepatocellular carcinoma Chemotherapy Portal vein embolization Hepatic arterial
